# What a cagrilintide combination changed in a basal insulin trial

- Article ID: research-057
- Product: Cagrilintide (cagrilintide-701)
- Canonical page: https://heritagebiolabs.com/research-library/articles/057-what-a-cagrilintide-combination-changed-in-a-basal-insulin-trial
- Product collection: https://heritagebiolabs.com/research-library/products/cagrilintide
- Product page: https://heritagebiolabs.com/product/cagrilintide-701
- Reading focus: Interpreting evidence (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains held together by peptide bonds. They can carry hormone signals that affect how the body uses nutrients. Cagrilintide is an investigational peptide designed to act like the hormone amylin for longer. In the 2026 REIMAGINE 3 study, researchers asked what changed when the cagrilintide–semaglutide combination, called CagriSema, was added to basal insulin in adults with type 2 diabetes. [1]

Basal insulin provides background insulin between meals and overnight. Some participants also took metformin. They still had blood sugar above the level targeted for inclusion in the trial. A total of 274 adults were randomly assigned to one of two study groups receiving the combination or to corresponding placebo groups. The placebo comparison allowed the investigators to see whether adding the tested combination changed outcomes in this setting. The question was about an additional treatment in people already receiving insulin. [1]

The trial’s main outcome was the change in HbA1c over 40 weeks. HbA1c gives a picture of average blood sugar over the preceding several months. Mean reductions were about 2.33 and 2.10 percentage points in the two combination groups, compared with about 0.66 percentage points in the pooled placebo groups under the trial’s efficacy analysis. Investigators also recorded weight reductions of around 10% to 12% in the active groups. These outcomes describe changes observed in a defined population and depend on the way the trial estimated effects. [1]

When testing glucose-lowering treatments alongside insulin, investigators monitor hypoglycemia, or excessively low blood sugar. The authors reported no severe hypoglycemia in this trial. That finding pertains to the enrolled participants, the trial’s monitoring and its duration. An uncommon event could still occur in a larger study or in a group with different health conditions. Gastrointestinal disorders were among the most common adverse events in the trial. Those events help explain why a report on blood sugar and body weight also describes what participants experienced during treatment. [1]

REIMAGINE 3 included a placebo comparison for CagriSema. It did not include a group receiving cagrilintide alone or a group receiving semaglutide alone. The measured HbA1c and weight changes therefore belong to the tested combination added to basal insulin. Researchers would need other comparisons to estimate the separate contribution of either component in this particular setting. Reading the intervention and comparator together makes the study’s answer specific enough to distinguish it from trials in people who do not use insulin. [1]

## Sources

1. Julio Rosenstock et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. The Lancet (publication 2026-06-07). <https://pubmed.ncbi.nlm.nih.gov/42251856/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 012 - Cagrilintide.docx; article 57; content SHA-256 0697e32676336c0f666f492f76f2b69496131863e9a0a42e42c9c182dfd015ec.
